| View this message online 
Hello manoj kumar valluru, We want to congratulate the company NeoStem for having what appears to be an independent group validate importance of their VSEL cells in the body's response to heart failure. In a recent paper a Polish group demonstrated that post-infarct there is an almost three-fold increase in VSEL stem cells entering circulation...this could provide a nice rationale for post-AMI therapy using these cells. Can these cells be mobilized by G-CSF? Would be neat to look !! A nice set of claims were issued in patent 7,470,538 last week. This covered the use of cord blood derived cells for treatment of cardiac ischemia. We thought that in general hematologists do not advocate using cord blood for other things than post transplant reconstitution...I guess that doesn't stop people from filing IP on them. Patent 7,470,537 was issued covering a cellular phenotype on fat stem cells. Interestingly on the USPTO site it did not have anyone mentioned as assignee. An interesting patent, 7,470,425, covered a composition of dissociated cells that have been combined with a "support material" and the used for regenerative purposes. It appears like the inventors came up with a really neat way of circumventing prior art that existed on stem cells and matrices by developing a new, non-obvious, and useful combination of the two. Happy New Year !!!!!!!!!!!
The 3rd Annual Stem Cells World Congress (20-22 January 2009)
The Stem Cell Meeting (March 2009)
Thanks again for your help in supporting StemCellPatents.com.
NEW -  (BETA) Now you can send our newsletters to your friends and colleagues using our quick and easy send-to-a-friend feature (BETA).
------------------------------------------------------------ To unsubscribe, click here. Delivered: Monday January 5th, 2009 @ 14:20:16 EST | 
